Should You Buy Vertex Before Feb. 12?
Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report earnings on Feb. 12. While there's never just one good time to buy a stock, here's a look at whether investors should buy the pharmaceutical stock before that date.
The company reported third-quarter earnings on Nov. 3. Revenue was up 11% year over year to $3.08 billion. However, earnings per share (EPS) rose only 4.7% to $4.20 as increased research and development expenses offset some of the revenue growth.
Investors did not react well to the report. The stock dropped more than 1% on the day earnings were announced and continued to fall by more than 3% over the next few days, mainly because sales of some of its newer therapies were underwhelming.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Und Vertex Pharmaceuticals Inc. steht derzeit mit 47 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung bei unserer Community hoch im Kurs.
Das Community-Kursziel von 461 € für Vertex Pharmaceuticals Inc. deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 374.1 € hin.
